Developing new indications
for approved medicines in hematological malignancies
using a proprietary continuous delivery platform.

Targeted continuous delivery

Each product we work on is reimagined and studied to develop new dose regimens and define optimal targets. Our approach establishes new indications and delivers superior outcomes.

Careers

We are building a team dedicated to delivering breakthrough, transformative products for patients with blood cancers. Learn more about career opportunities at Starton.

News and Events

09/14/20

Keith Darragh Joins Starton Therapeutics as Chief Financial Officer

NEW YORK, N.Y., September 14, 2020 – Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical stage biotechnology powering continuous delivery of approved drugs for novel indications, announced today…

09/09/20

Drs. Kenneth Anderson and Asher Chanan-Khan to Join Starton Therapeutics Board of Directors 

NEW YORK, N.Y., September 9, 2020 – Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical stage biotechnology company powering continuous delivery of approved drugs in novel indications, announced…